Equillium (NYSE:EQ) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $20.50 for the company and are predicting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given Equillium an industry rank of 98 out of 257 based on the ratings given to related companies.

A number of research firms have recently commented on EQ. Jefferies Financial Group began coverage on shares of Equillium in a research note on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. Stifel Nicolaus began coverage on shares of Equillium in a research note on Tuesday. They set a “buy” rating and a $22.00 price objective for the company.

Equillium stock opened at $16.50 on Wednesday. Equillium has a one year low of $9.21 and a one year high of $19.27.

About Equillium

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma.

Read More: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Equillium (EQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.